Skip to main content
Fig. 4 | Molecular Medicine

Fig. 4

From: Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy

Fig. 4

NAT10 promotes PD-L1 transcription in an NPM1-dependent manner. A PD-L1 protein expression in the indicated cells transfected with control shRNA (nc), NAT10 shRNAs (sh-NAT10-1, sh-NAT10-2), empty vector, or the NAT10 overexpression plasmid (NAT10 oe). B PD-L1 mRNA levels were quantified by RT‒qPCR. C PD-L1 promoter activity was quantified by a dual-luciferase assay. D Cell surface PD-L1 expression on MDA-MB-231 cells was examined by flow cytometry (left), and the mean fluorescence intensity (MFI) of PD-L1 was measured (right). E MDA-MB-231 cells with stable knockdown of NPM1 were transiently transfected with or without the NAT10 overexpression plasmid. Data are presented as the mean ± s.d. of three independent experiments. *P < 0.05, **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significantly different

Back to article page